Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Jun 30, 2019
Mar 31, 2019
Dec 31, 2018
Sep 30, 2018
Total Revenue
387,763
400,745
353,214
391,706
Cost of Revenue
77,436
89,182
75,019
78,893
Gross Profit
310,327
311,563
278,195
312,813
Operating Expenses
Research Development
185,641
183,591
175,390
161,408
Selling General and Administrative
160,754
162,158
164,171
148,566
Non Recurring
--
--
--
--
Others
20,286
19,765
6,782
18,580
Total Operating Expenses
366,681
365,514
346,343
328,554
Operating Income or Loss
(56,354)
(53,951)
(68,148)
(15,741)
Income from Continuing Operations
Total Other Income/Expenses Net
15,426
1,423
26,893
2,121
Earnings Before Interest And Taxes
(35,495)
(46,230)
(36,157)
(8,290)
Interest Expense
6,400
6,727
7,154
11,123
Income Before Tax
(41,895)
(52,957)
(43,311)
(19,413)
Income Tax Expense
(4,460)
3,516
(39,661)
(6,793)
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(37,435)
(56,473)
(3,650)
(12,620)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(37,435)
(56,473)
(3,650)
(12,620)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(37,435)
(56,473)
(3,650)
(12,620)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information